Prevalence of Low Testosterone in Men With Cystic Fibrosis and Congenital Bilateral Absence of the Vas Deferens: A Cross-sectional Study Using a Large, Multi-institutional Database.


Journal

Urology
ISSN: 1527-9995
Titre abrégé: Urology
Pays: United States
ID NLM: 0366151

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 15 06 2023
revised: 23 08 2023
accepted: 30 08 2023
medline: 11 12 2023
pubmed: 17 9 2023
entrez: 16 9 2023
Statut: ppublish

Résumé

To investigate the prevalence and treatment rates of low testosterone (T) in men with cystic fibrosis (CF). CF is a genetic disease with highly variable presentation that results from a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Phenotypic manifestations of CF include alterations in function of the lungs, liver, pancreas, and reproductive system. Despite the well-described association between CF and infertility secondary to congenital bilateral absence of the vas deferens (CBAVD), men with CF report further sexual and reproductive health concerns, many of which are often associated with low testosterone. We queried the TrinetX database for men over 18years old with CF or CBAVD to assess what percentage of men had a T level measured, and if hypogonadal (below 300 ng/dL), what percentage received T therapy (TT). We hypothesized that low T would be under-evaluated in the CF population. Serum T levels were measured in 10.1% of men with CF and 8.9% of men with CBAVD. Within each group, 464 men with CF (32.7%) and 132 with CBAVD (43.0%) demonstrated low T. The majority of men with T < 300 ng/dL went on to appropriately receive TT: 59.3% of men with CF and 78% with CBAVD. Our data suggests that hypogonadism is highly prevalent in men with CF and CBAVD. Investigation and appropriate treatment of testosterone deficiency may significantly improve quality of life.

Identifiants

pubmed: 37716455
pii: S0090-4295(23)00796-3
doi: 10.1016/j.urology.2023.08.039
pii:
doi:

Substances chimiques

Cystic Fibrosis Transmembrane Conductance Regulator 126880-72-6
Testosterone 3XMK78S47O

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

143-148

Subventions

Organisme : NIDDK NIH HHS
ID : UE5 DK137308
Pays : United States

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest Ranjith Ramasamy receives funding from NIH (DK130991) and Cystic Fibrosis Foundation. The other authors have no conflict of interest to declare.

Auteurs

Katherine Campbell (K)

Desai Sethi Urology Institute, University of Miami, Miami, FL.

Nicholas Deebel (N)

Department of Urology, Wake Forest University School of Medicine, Winston-Salem, NC.

Taylor Kohn (T)

Brady Urological Institute, Johns Hopkins Medicine, Baltimore, MD.

Rachel Passarelli (R)

Department of Urology, Rutgers - Robert Wood Johnson, New Brunswick, NJ.

Danielle Velez (D)

Department of Urology, Rutgers - Robert Wood Johnson, New Brunswick, NJ.

Ranjith Ramasamy (R)

Desai Sethi Urology Institute, University of Miami, Miami, FL. Electronic address: ramasamy@miami.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH